Genmab — Februar 2017
-
Darabliver ikke first in class, men måske er de best in class, men de skal være "meget" best in class for at skubbe allerede godkendte behandlinger ud og jeg tror nok der kommer en del andre stoffer der angriber cd38 før Dara, men kan være jeg tager fejl da nogle af samarbejdspartnerne arbejder effektivt, men det er et kapløb, hvis de altså ikke er en del bedre.
-
-
måske davors link fra i aftes:-)
-
Super http://immunosym.org/daily-news/preclinical-work-suggests-combined-pd-l1-and-cd38-inhibition-may-improve-tumor-response?et_cid=38978774&et_rid=934849930&linkid=IO17_79 fra davor. Optimismen omkring dara i solide tumorer spirer, og hvis man begynder at indregne en 20-25% sandsynlighed for succes, så kan det rykke ganske betragteligt ved værdiansættelsen
-
Denne perlerække af små film er sluppet ud fra Genmabs laboratorium - http://www.discovery.com/tv-shows/mythbusters/videos/knock-your-socks-off/
Knock your socks off!
-
-
Here is a taste that will just knock your socks off...
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind